Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvovaginal Candidiases
Conditions
Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Trial Timeline
Dec 1, 2019 → Dec 1, 2020
NCT ID
NCT03167957About Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)
Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB) is a phase 2 stage product being developed by Matinas Biopharma for Vulvovaginal Candidiases. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03167957. Target conditions include Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis.
What happened to similar drugs?
1 of 8 similar drugs in Vulvovaginal Candidiases were approved
Approved (1) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03167957 | Phase 2 | Withdrawn |
Competing Products
10 competing products in Vulvovaginal Candidiases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal | Novo Nordisk | Phase 3 | 40 |
| Fluconazole | Pfizer | Phase 3 | 40 |
| Clotrimazole vaginal tablet + Fluconazole | Bayer | Approved | 40 |
| SCY-078 + Fluconazole | Scynexis | Phase 2 | 25 |
| Ibrexafungerp | Scynexis | Phase 3 | 30 |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Scynexis | Phase 3 | 30 |
| Ibrexafungerp | Scynexis | Phase 1 | 19 |
| Estradiol + Placebo | TherapeuticsMD | Phase 3 | 30 |